Active Surveillance Is the Preferred Approach to Clinical Stage I Testicular Cancer
- 1 October 2013
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (28) , 3490-3493
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Barriers to the Implementation of Surveillance for Stage I Testicular SeminomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study GroupJournal of Clinical Oncology, 2011
- Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapiesAnnals of Oncology, 2010
- Management of testicular neoplasms in France and compliance with national guidelines.Journal of Clinical Oncology, 2010
- Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacyAnnals of Oncology, 2009
- European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part IEuropean Urology, 2008
- Initial versus recent outcomes with a non–risk adapted surveillance policy in stage I non-seminomatous germ cell tumors (NSGCT)Journal of Clinical Oncology, 2007
- The changing presentation of germ cell tumours of the testis between 1983 and 2002BJU International, 2005
- Mortality After Cure of Testicular SeminomaJournal of Clinical Oncology, 2004
- Risk of Second Malignant Neoplasms Among Long-term Survivors of Testicular CancerJNCI: Journal of the National Cancer Institute, 1997